EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (79%) **Content type:** Clinical